Cellular and molecular pharmacology of antiestrogen action and resistance.
about
Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathwayGREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancerRegulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifenModulation of xenobiotic receptors by steroidsMinireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancersAutophagy and endocrine resistance in breast cancerA small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer.Regulation of Estrogen Receptor α by the SET7 Lysine MethyltransferaseInfluence of berry polyphenols on receptor signaling and cell-death pathways: implications for breast cancer preventionp21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cellsFunctional implications of altered subcellular localization of PELP1 in breast cancer cells.Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumorsOncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptorConstitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancerEndoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogensBCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells.Pathways to tamoxifen resistance.The properties of high-dimensional data spaces: implications for exploring gene and protein expression data.Integrative "omic" analysis for tamoxifen sensitivity through cell based models.Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis.The role of preclinical animal models in breast cancer drug development.Stapled BIG3 helical peptide ERAP potentiates anti-tumour activity for breast cancer therapeutics.Sensitization of tamoxifen-resistant breast cancer cells by Z-ligustilide through inhibiting autophagy and accumulating DNA damagesThe Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF7 cells.CAPER, a novel regulator of human breast cancer progression.Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent mannerProlylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells.Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer's Abeta Peptide.Mechanism of estradiol-induced block of voltage-gated K+ currents in rat medial preoptic neurons.Function of RasGRP3 in the formation and progression of human breast cancerThe effects of tamoxifen on immunity.Arsenic abrogates the estrogen-signaling pathway in the rat uterusRon receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell linesKnockdown of estrogen receptor-α induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death.IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.17Beta-estradiol elevates cGMP and, via plasma membrane recruitment of protein kinase GIalpha, stimulates Ca2+ efflux from rat hepatocytes.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cellsDynamic modelling of oestrogen signalling and cell fate in breast cancer cells
P2860
Q21195156-68882754-DA07-4153-A348-F289D1EA55EDQ21560759-CFB8E22B-2CDB-4861-8FD7-FA1E911B4DE9Q24632895-1D489A18-C9C1-44B9-8B83-C4803C2C6720Q27009230-C67E8F2F-ACAA-4237-A046-68101F3958A7Q27016106-FCF8BB81-53BF-4F1E-9FFD-674AAE635188Q27023375-0E058236-6784-427A-A7B1-530BEDC44EBCQ27345313-39B53F32-B275-4DFF-8906-81FD2503674CQ27650581-58607B2D-AFA7-4ACA-BFA5-120B3504EB6AQ28258801-B36821ED-D5D2-4DCB-BB34-168357A15605Q28269662-669634AF-D566-4103-8B07-EA9EDB4D3148Q28270490-95A88232-1493-4D0E-BE58-4EF8EA108223Q28296627-F169D60E-AF29-48AF-A4E2-74B00A604BF5Q28304891-0CD9F4F4-6147-41CE-AB03-60DD3E2D6CC5Q28475229-A45E57BB-5389-4364-AB5E-F75D75F05A61Q28485336-6CFFAB3F-2583-4BBF-91D8-181BE1EB96B6Q30432099-5177DEF2-E7E6-46B2-9A91-82F515C95738Q30441001-51640F5E-3B3E-44F2-8D14-898A4DFFEB44Q31140694-EEB05474-205F-4A79-A5A1-6FDA6EEC3720Q31156438-42593A3A-C810-4D40-A059-6CAC16D0C847Q33523022-7AE72A30-95EA-490F-8461-37E4A4F7B35DQ33555575-77E827C3-D457-4577-9142-EF74B2224731Q33687329-7CA36FE1-62A5-4391-A133-A5283150F218Q33710104-21214035-AD22-432A-AD4A-2F0F28157142Q33723383-CCE07C8A-9585-4CF6-9AB3-FF69E4B4DA84Q33728372-ABC475E4-9504-469B-A11A-DC8BAE06255CQ33746249-F1AAFDBC-AE3D-4EC1-9AEA-EE5178BDCF93Q33750907-A4332D67-6D5A-4994-B032-A5600F16EC7BQ33813981-645A878D-3461-4DE8-9CEF-8109ABB79141Q33839260-17145E2E-7113-49A6-8533-92D78C29C4A0Q33916244-BC87048F-9374-4DEC-B80B-382468432667Q33960160-6D89BE4B-71AD-490D-983A-EF0611F2A403Q33989185-A4F0C3FE-79A1-4B99-AB93-3135EA435973Q34016904-E76941C2-6A3A-45A5-9E14-FD9708DF8987Q34041328-E97E2CD7-B4F2-4B78-81F3-87E38EE928B8Q34072615-727E2620-E109-47BA-BD51-834CDFF16C44Q34078171-A4F82814-85D6-4003-B276-3985D1440EF4Q34094527-F160915D-DD06-440E-9B1F-F166B996C453Q34147910-EB715B73-49C7-4121-9F34-FC3166FD5193Q34156192-67F9F01A-49BC-42E1-A24A-3CC71BCF7B21Q34192940-25282CCC-CFC7-49CC-BD1A-1FF2C165311C
P2860
Cellular and molecular pharmacology of antiestrogen action and resistance.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Cellular and molecular pharmacology of antiestrogen action and resistance.
@ast
Cellular and molecular pharmacology of antiestrogen action and resistance.
@en
type
label
Cellular and molecular pharmacology of antiestrogen action and resistance.
@ast
Cellular and molecular pharmacology of antiestrogen action and resistance.
@en
prefLabel
Cellular and molecular pharmacology of antiestrogen action and resistance.
@ast
Cellular and molecular pharmacology of antiestrogen action and resistance.
@en
P2093
P1476
Cellular and molecular pharmacology of antiestrogen action and resistance.
@en
P2093
P577
2001-03-01T00:00:00Z